| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 185 | 2024 | 2498 | 7.030 |
Why?
|
| Receptors, Estrogen | 64 | 2024 | 797 | 2.160 |
Why?
|
| Receptor, ErbB-2 | 35 | 2023 | 514 | 1.900 |
Why?
|
| Tamoxifen | 30 | 2020 | 363 | 1.730 |
Why?
|
| Antineoplastic Agents, Hormonal | 25 | 2021 | 256 | 1.630 |
Why?
|
| Drug Resistance, Neoplasm | 32 | 2024 | 717 | 1.500 |
Why?
|
| Triple Negative Breast Neoplasms | 10 | 2024 | 235 | 1.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 45 | 2021 | 1893 | 1.250 |
Why?
|
| Gene Expression Profiling | 41 | 2021 | 1702 | 1.230 |
Why?
|
| Antineoplastic Agents | 34 | 2023 | 1660 | 1.220 |
Why?
|
| Biomarkers, Tumor | 36 | 2024 | 1484 | 1.170 |
Why?
|
| Signal Transduction | 45 | 2021 | 4501 | 1.040 |
Why?
|
| Receptors, Progesterone | 30 | 2021 | 878 | 1.020 |
Why?
|
| Cell Line, Tumor | 56 | 2024 | 3337 | 1.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 23 | 2024 | 1214 | 0.990 |
Why?
|
| Female | 242 | 2025 | 66482 | 0.950 |
Why?
|
| Mammary Neoplasms, Experimental | 22 | 2017 | 247 | 0.940 |
Why?
|
| Mammary Glands, Animal | 17 | 2022 | 481 | 0.920 |
Why?
|
| Estrogen Receptor alpha | 17 | 2021 | 468 | 0.900 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 26 | 2014 | 1016 | 0.850 |
Why?
|
| Humans | 304 | 2025 | 124593 | 0.820 |
Why?
|
| Neoplasms | 19 | 2024 | 2771 | 0.800 |
Why?
|
| Genomics | 7 | 2018 | 1500 | 0.800 |
Why?
|
| Quinazolines | 16 | 2023 | 174 | 0.790 |
Why?
|
| Cell Proliferation | 33 | 2024 | 2285 | 0.770 |
Why?
|
| Mice | 102 | 2025 | 17630 | 0.750 |
Why?
|
| Neoadjuvant Therapy | 21 | 2023 | 337 | 0.720 |
Why?
|
| Animals | 123 | 2025 | 34072 | 0.700 |
Why?
|
| Bayes Theorem | 3 | 2024 | 284 | 0.700 |
Why?
|
| Neoplasm Staging | 25 | 2022 | 1248 | 0.690 |
Why?
|
| Neoplasm Metastasis | 17 | 2025 | 665 | 0.680 |
Why?
|
| Xenograft Model Antitumor Assays | 20 | 2024 | 882 | 0.660 |
Why?
|
| Mammary Neoplasms, Animal | 6 | 2022 | 139 | 0.660 |
Why?
|
| Cell Transformation, Neoplastic | 17 | 2022 | 616 | 0.640 |
Why?
|
| Prognosis | 59 | 2021 | 4625 | 0.640 |
Why?
|
| Models, Statistical | 5 | 2018 | 471 | 0.610 |
Why?
|
| Apoptosis | 29 | 2024 | 1789 | 0.600 |
Why?
|
| Genetic Testing | 7 | 2017 | 1001 | 0.600 |
Why?
|
| Neoplasm Recurrence, Local | 15 | 2022 | 1140 | 0.590 |
Why?
|
| Estradiol | 17 | 2020 | 535 | 0.590 |
Why?
|
| Information Dissemination | 4 | 2014 | 186 | 0.590 |
Why?
|
| ErbB Receptors | 12 | 2021 | 281 | 0.580 |
Why?
|
| Neoplastic Stem Cells | 9 | 2015 | 291 | 0.560 |
Why?
|
| Ovarian Neoplasms | 8 | 2011 | 418 | 0.560 |
Why?
|
| Survival Analysis | 23 | 2020 | 1496 | 0.560 |
Why?
|
| Uterine Cervical Neoplasms | 8 | 2023 | 237 | 0.550 |
Why?
|
| Taxoids | 12 | 2017 | 67 | 0.540 |
Why?
|
| Mammary Tumor Virus, Mouse | 13 | 2018 | 106 | 0.530 |
Why?
|
| Transcription Factor AP-1 | 9 | 2016 | 105 | 0.530 |
Why?
|
| Precancerous Conditions | 7 | 2018 | 282 | 0.530 |
Why?
|
| Middle Aged | 90 | 2025 | 26714 | 0.520 |
Why?
|
| STAT5 Transcription Factor | 5 | 2022 | 89 | 0.510 |
Why?
|
| Estrogens | 12 | 2020 | 513 | 0.500 |
Why?
|
| Mice, Nude | 26 | 2021 | 707 | 0.500 |
Why?
|
| Epithelial Cells | 13 | 2022 | 909 | 0.490 |
Why?
|
| STAT3 Transcription Factor | 6 | 2015 | 221 | 0.480 |
Why?
|
| Adenocarcinoma | 12 | 2024 | 1022 | 0.480 |
Why?
|
| Data Interpretation, Statistical | 2 | 2012 | 231 | 0.470 |
Why?
|
| Carcinoma, Ductal, Breast | 7 | 2015 | 83 | 0.460 |
Why?
|
| Genetic Counseling | 2 | 2018 | 220 | 0.460 |
Why?
|
| Tumor Suppressor Protein p53 | 14 | 2015 | 723 | 0.460 |
Why?
|
| Gene Expression | 13 | 2020 | 1561 | 0.450 |
Why?
|
| Chemotherapy, Adjuvant | 9 | 2017 | 361 | 0.450 |
Why?
|
| Breast | 9 | 2022 | 214 | 0.440 |
Why?
|
| Mutation | 23 | 2021 | 5825 | 0.430 |
Why?
|
| Trastuzumab | 14 | 2023 | 134 | 0.420 |
Why?
|
| Aged | 66 | 2025 | 19703 | 0.420 |
Why?
|
| Molecular Targeted Therapy | 6 | 2020 | 354 | 0.420 |
Why?
|
| Biomedical Research | 3 | 2021 | 517 | 0.420 |
Why?
|
| Adult | 74 | 2024 | 29438 | 0.410 |
Why?
|
| Cyclin-Dependent Kinase 6 | 2 | 2024 | 41 | 0.410 |
Why?
|
| Cyclin-Dependent Kinase 4 | 2 | 2024 | 58 | 0.400 |
Why?
|
| Aromatase Inhibitors | 4 | 2020 | 76 | 0.400 |
Why?
|
| Tumor Cells, Cultured | 28 | 2021 | 1062 | 0.390 |
Why?
|
| Receptors, G-Protein-Coupled | 5 | 2021 | 292 | 0.390 |
Why?
|
| Stem Cells | 6 | 2018 | 692 | 0.390 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 4 | 2021 | 63 | 0.380 |
Why?
|
| Tetrahydronaphthalenes | 6 | 2009 | 29 | 0.380 |
Why?
|
| Phosphorylation | 15 | 2021 | 1615 | 0.360 |
Why?
|
| Anticarcinogenic Agents | 8 | 2009 | 56 | 0.360 |
Why?
|
| Estrogen Antagonists | 6 | 2020 | 103 | 0.360 |
Why?
|
| Receptors, Androgen | 4 | 2025 | 413 | 0.350 |
Why?
|
| Risk Management | 1 | 2011 | 68 | 0.350 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2020 | 1108 | 0.340 |
Why?
|
| Pyrazoles | 3 | 2025 | 306 | 0.340 |
Why?
|
| Mice, Transgenic | 25 | 2018 | 2392 | 0.340 |
Why?
|
| Interleukin-8 | 3 | 2016 | 208 | 0.330 |
Why?
|
| Neoplasms, Hormone-Dependent | 6 | 2018 | 100 | 0.330 |
Why?
|
| Research Design | 7 | 2016 | 691 | 0.330 |
Why?
|
| Disease-Free Survival | 16 | 2017 | 869 | 0.330 |
Why?
|
| Pancreatic Neoplasms | 6 | 2024 | 691 | 0.320 |
Why?
|
| Treatment Outcome | 39 | 2025 | 12322 | 0.320 |
Why?
|
| Disease Models, Animal | 19 | 2021 | 4350 | 0.320 |
Why?
|
| Lung Neoplasms | 12 | 2023 | 1645 | 0.320 |
Why?
|
| Protein Kinase Inhibitors | 6 | 2024 | 529 | 0.310 |
Why?
|
| Neoplasm Transplantation | 16 | 2021 | 374 | 0.310 |
Why?
|
| Lymphatic Metastasis | 19 | 2013 | 414 | 0.310 |
Why?
|
| Consumer Health Information | 1 | 2009 | 25 | 0.310 |
Why?
|
| Medical Oncology | 3 | 2021 | 212 | 0.310 |
Why?
|
| Ethics, Medical | 1 | 2011 | 395 | 0.310 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2017 | 259 | 0.310 |
Why?
|
| Mastectomy | 7 | 2017 | 64 | 0.300 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 3 | 2015 | 66 | 0.300 |
Why?
|
| Community Participation | 1 | 2009 | 44 | 0.300 |
Why?
|
| Public Opinion | 1 | 2009 | 56 | 0.300 |
Why?
|
| Papillomavirus Infections | 2 | 2023 | 292 | 0.300 |
Why?
|
| Repressor Proteins | 5 | 2014 | 816 | 0.300 |
Why?
|
| Insulin-Like Growth Factor I | 7 | 2011 | 341 | 0.300 |
Why?
|
| Transcriptome | 6 | 2019 | 952 | 0.300 |
Why?
|
| Nuclear Receptor Coactivators | 3 | 2014 | 72 | 0.300 |
Why?
|
| Arthralgia | 2 | 2019 | 54 | 0.300 |
Why?
|
| Cell Division | 19 | 2013 | 777 | 0.290 |
Why?
|
| Neoplasms, Experimental | 5 | 2017 | 210 | 0.290 |
Why?
|
| Antineoplastic Agents, Phytogenic | 8 | 2005 | 99 | 0.290 |
Why?
|
| Computer Terminals | 1 | 2007 | 2 | 0.290 |
Why?
|
| Asthenopia | 1 | 2007 | 2 | 0.290 |
Why?
|
| Eye Protective Devices | 1 | 2007 | 7 | 0.290 |
Why?
|
| Paclitaxel | 8 | 2024 | 125 | 0.290 |
Why?
|
| DNA Repair | 4 | 2019 | 585 | 0.290 |
Why?
|
| RNA, Messenger | 20 | 2023 | 2816 | 0.280 |
Why?
|
| Genes, BRCA1 | 4 | 2012 | 50 | 0.280 |
Why?
|
| Ophthalmic Solutions | 1 | 2007 | 91 | 0.280 |
Why?
|
| Breast Diseases | 2 | 2016 | 35 | 0.280 |
Why?
|
| Neoplasm Invasiveness | 12 | 2021 | 617 | 0.270 |
Why?
|
| Physician's Role | 1 | 2009 | 165 | 0.270 |
Why?
|
| Internet | 2 | 2009 | 375 | 0.270 |
Why?
|
| Epithelial-Mesenchymal Transition | 3 | 2017 | 214 | 0.270 |
Why?
|
| Social Support | 1 | 2009 | 329 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2024 | 841 | 0.270 |
Why?
|
| Aged, 80 and over | 22 | 2025 | 6533 | 0.260 |
Why?
|
| Pyridines | 4 | 2024 | 229 | 0.260 |
Why?
|
| Gene Expression Regulation | 12 | 2016 | 2521 | 0.260 |
Why?
|
| Kaplan-Meier Estimate | 11 | 2021 | 1032 | 0.260 |
Why?
|
| Mice, SCID | 9 | 2021 | 568 | 0.260 |
Why?
|
| Clinical Trials as Topic | 8 | 2015 | 1089 | 0.260 |
Why?
|
| Tears | 1 | 2007 | 172 | 0.250 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 4 | 2023 | 74 | 0.250 |
Why?
|
| Transcription, Genetic | 9 | 2017 | 1697 | 0.250 |
Why?
|
| Male | 57 | 2025 | 61191 | 0.250 |
Why?
|
| Interleukin-6 | 4 | 2017 | 419 | 0.250 |
Why?
|
| Janus Kinase 2 | 2 | 2018 | 132 | 0.250 |
Why?
|
| Antibodies, Monoclonal, Humanized | 10 | 2020 | 505 | 0.250 |
Why?
|
| Pancreatectomy | 4 | 2010 | 137 | 0.240 |
Why?
|
| Nuclear Receptor Coactivator 3 | 5 | 2016 | 348 | 0.240 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2025 | 35 | 0.240 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 12 | 2 | 2018 | 19 | 0.240 |
Why?
|
| MCF-7 Cells | 7 | 2020 | 222 | 0.230 |
Why?
|
| Informed Consent | 4 | 2013 | 334 | 0.230 |
Why?
|
| Viral Tropism | 1 | 2025 | 43 | 0.230 |
Why?
|
| Computer Simulation | 2 | 2016 | 646 | 0.230 |
Why?
|
| Promoter Regions, Genetic | 8 | 2016 | 1327 | 0.230 |
Why?
|
| Ki-67 Antigen | 6 | 2014 | 113 | 0.230 |
Why?
|
| Phosphatidylinositol 3-Kinases | 5 | 2019 | 337 | 0.230 |
Why?
|
| Cell Movement | 9 | 2021 | 836 | 0.230 |
Why?
|
| Carcinoma, Lobular | 3 | 2010 | 24 | 0.230 |
Why?
|
| Neoplasm Proteins | 6 | 2016 | 669 | 0.220 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2025 | 88 | 0.220 |
Why?
|
| Pyrophosphatases | 1 | 2024 | 20 | 0.220 |
Why?
|
| Wnt1 Protein | 4 | 2018 | 71 | 0.220 |
Why?
|
| Genes, p53 | 7 | 2004 | 212 | 0.220 |
Why?
|
| Time Factors | 21 | 2021 | 6292 | 0.220 |
Why?
|
| Dry Eye Syndromes | 1 | 2007 | 268 | 0.220 |
Why?
|
| Protein Array Analysis | 4 | 2018 | 101 | 0.220 |
Why?
|
| Neurofibromin 1 | 2 | 2023 | 41 | 0.220 |
Why?
|
| Dependovirus | 1 | 2025 | 127 | 0.220 |
Why?
|
| Prostatic Neoplasms | 5 | 2017 | 1544 | 0.220 |
Why?
|
| DNA Methylation | 4 | 2022 | 1003 | 0.210 |
Why?
|
| Germ-Line Mutation | 2 | 2024 | 332 | 0.210 |
Why?
|
| Keratin-6 | 2 | 2015 | 13 | 0.210 |
Why?
|
| Oncolytic Viruses | 1 | 2024 | 73 | 0.210 |
Why?
|
| Cell Survival | 11 | 2021 | 806 | 0.210 |
Why?
|
| Piperazines | 2 | 2024 | 236 | 0.210 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 5145 | 0.210 |
Why?
|
| Progesterone | 4 | 2017 | 623 | 0.200 |
Why?
|
| Proteogenomics | 1 | 2023 | 68 | 0.200 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 14 | 2010 | 1284 | 0.200 |
Why?
|
| Genetic Vectors | 4 | 2025 | 940 | 0.200 |
Why?
|
| Antibodies, Monoclonal | 5 | 2010 | 1018 | 0.200 |
Why?
|
| Transfection | 15 | 2013 | 1061 | 0.200 |
Why?
|
| Carrier Proteins | 4 | 2014 | 1022 | 0.200 |
Why?
|
| Genetic Research | 2 | 2013 | 55 | 0.200 |
Why?
|
| Tumor Stem Cell Assay | 10 | 2011 | 33 | 0.190 |
Why?
|
| Thrombocytopenia | 1 | 2024 | 221 | 0.190 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2018 | 184 | 0.190 |
Why?
|
| Emphysema | 2 | 2014 | 67 | 0.190 |
Why?
|
| Proportional Hazards Models | 14 | 2014 | 1350 | 0.190 |
Why?
|
| Heat-Shock Proteins | 6 | 2001 | 195 | 0.190 |
Why?
|
| Cisplatin | 5 | 2017 | 236 | 0.190 |
Why?
|
| Cell Cycle | 10 | 2016 | 610 | 0.190 |
Why?
|
| Pleural Neoplasms | 1 | 2023 | 70 | 0.190 |
Why?
|
| Protein Tyrosine Phosphatases | 2 | 2016 | 78 | 0.190 |
Why?
|
| Cluster Analysis | 4 | 2018 | 398 | 0.190 |
Why?
|
| Tumor Microenvironment | 5 | 2024 | 555 | 0.190 |
Why?
|
| DNA, Neoplasm | 9 | 2012 | 301 | 0.190 |
Why?
|
| S Phase | 5 | 1998 | 73 | 0.190 |
Why?
|
| Metformin | 1 | 2023 | 151 | 0.190 |
Why?
|
| Mesothelioma | 1 | 2023 | 87 | 0.190 |
Why?
|
| Brain Neoplasms | 3 | 2020 | 1207 | 0.190 |
Why?
|
| Financing, Organized | 1 | 2021 | 19 | 0.190 |
Why?
|
| Genetic Privacy | 2 | 2011 | 42 | 0.180 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2017 | 465 | 0.180 |
Why?
|
| Minority Groups | 2 | 2020 | 247 | 0.180 |
Why?
|
| Dose-Response Relationship, Drug | 14 | 2021 | 1689 | 0.180 |
Why?
|
| Genome, Human | 4 | 2011 | 1273 | 0.180 |
Why?
|
| Immunohistochemistry | 14 | 2015 | 1690 | 0.180 |
Why?
|
| Health Care Surveys | 3 | 2011 | 287 | 0.180 |
Why?
|
| Algorithms | 5 | 2022 | 1619 | 0.170 |
Why?
|
| Tenascin | 2 | 2017 | 31 | 0.170 |
Why?
|
| Transplantation, Heterologous | 13 | 2011 | 254 | 0.170 |
Why?
|
| Up-Regulation | 5 | 2015 | 862 | 0.170 |
Why?
|
| Abdomen | 4 | 1997 | 127 | 0.170 |
Why?
|
| Transcription Factors | 8 | 2019 | 2582 | 0.170 |
Why?
|
| Aging | 4 | 2001 | 1182 | 0.170 |
Why?
|
| Biomarkers | 8 | 2021 | 3063 | 0.170 |
Why?
|
| Wnt Proteins | 1 | 2021 | 193 | 0.170 |
Why?
|
| Retrospective Studies | 26 | 2023 | 16314 | 0.170 |
Why?
|
| Heterografts | 5 | 2021 | 171 | 0.170 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2011 | 92 | 0.170 |
Why?
|
| Predictive Value of Tests | 10 | 2013 | 2154 | 0.170 |
Why?
|
| Gene Amplification | 3 | 2019 | 228 | 0.170 |
Why?
|
| Indoles | 2 | 2018 | 179 | 0.170 |
Why?
|
| Research Personnel | 1 | 2021 | 117 | 0.170 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2021 | 205 | 0.170 |
Why?
|
| Anemia | 1 | 2024 | 339 | 0.170 |
Why?
|
| Genes, erbB-2 | 6 | 2010 | 37 | 0.170 |
Why?
|
| Methylphenidate | 1 | 2020 | 58 | 0.170 |
Why?
|
| RNA, Small Interfering | 8 | 2016 | 660 | 0.170 |
Why?
|
| Mitogen-Activated Protein Kinases | 6 | 2014 | 206 | 0.170 |
Why?
|
| Disclosure | 2 | 2018 | 148 | 0.170 |
Why?
|
| Carcinogenesis | 4 | 2015 | 331 | 0.170 |
Why?
|
| Postoperative Complications | 8 | 2013 | 3065 | 0.170 |
Why?
|
| Blotting, Western | 11 | 2010 | 1102 | 0.170 |
Why?
|
| Mevalonic Acid | 1 | 2019 | 19 | 0.160 |
Why?
|
| Hypothalamic Diseases | 1 | 2020 | 37 | 0.160 |
Why?
|
| Tissue Array Analysis | 6 | 2021 | 137 | 0.160 |
Why?
|
| GTPase-Activating Proteins | 2 | 2010 | 86 | 0.160 |
Why?
|
| Research Subjects | 2 | 2013 | 54 | 0.160 |
Why?
|
| Parents | 2 | 2018 | 1015 | 0.160 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 2 | 2016 | 48 | 0.160 |
Why?
|
| TOR Serine-Threonine Kinases | 3 | 2018 | 430 | 0.160 |
Why?
|
| Cholecalciferol | 1 | 2019 | 22 | 0.160 |
Why?
|
| Smoking | 4 | 2014 | 1045 | 0.160 |
Why?
|
| Central Nervous System Stimulants | 1 | 2020 | 127 | 0.160 |
Why?
|
| Pancreatic Fistula | 2 | 2010 | 29 | 0.160 |
Why?
|
| Selective Estrogen Receptor Modulators | 4 | 2011 | 60 | 0.160 |
Why?
|
| Mice, Inbred C57BL | 13 | 2018 | 4406 | 0.160 |
Why?
|
| Safety-net Providers | 1 | 2020 | 52 | 0.160 |
Why?
|
| Mice, Inbred NOD | 5 | 2021 | 285 | 0.160 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 113 | 0.160 |
Why?
|
| Consent Forms | 2 | 2011 | 22 | 0.160 |
Why?
|
| Lymph Nodes | 4 | 1997 | 382 | 0.160 |
Why?
|
| Cinnamates | 1 | 2018 | 15 | 0.160 |
Why?
|
| Estrogen Receptor Modulators | 3 | 2004 | 38 | 0.160 |
Why?
|
| Young Adult | 9 | 2024 | 9014 | 0.160 |
Why?
|
| Head and Neck Neoplasms | 1 | 2023 | 490 | 0.150 |
Why?
|
| Trans-Activators | 6 | 2005 | 800 | 0.150 |
Why?
|
| Databases, Factual | 4 | 2019 | 1177 | 0.150 |
Why?
|
| Transgenes | 6 | 2025 | 334 | 0.150 |
Why?
|
| Oncologists | 1 | 2018 | 29 | 0.150 |
Why?
|
| Protons | 1 | 2018 | 92 | 0.150 |
Why?
|
| Exome | 2 | 2024 | 1034 | 0.150 |
Why?
|
| Colorectal Neoplasms | 3 | 2020 | 570 | 0.150 |
Why?
|
| Camptothecin | 5 | 1999 | 73 | 0.150 |
Why?
|
| Craniospinal Irradiation | 1 | 2018 | 58 | 0.150 |
Why?
|
| Histone Deacetylases | 2 | 2011 | 110 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2019 | 406 | 0.140 |
Why?
|
| Bacterial Proteins | 4 | 2019 | 889 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2018 | 91 | 0.140 |
Why?
|
| Promyelocytic Leukemia Protein | 1 | 2017 | 12 | 0.140 |
Why?
|
| Survival Rate | 13 | 2010 | 2044 | 0.140 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2017 | 33 | 0.140 |
Why?
|
| Nanocapsules | 1 | 2017 | 7 | 0.140 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2017 | 31 | 0.140 |
Why?
|
| Receptors, Cell Surface | 2 | 2018 | 469 | 0.140 |
Why?
|
| Nuclear Proteins | 6 | 2014 | 1265 | 0.140 |
Why?
|
| Claudins | 2 | 2014 | 29 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2021 | 693 | 0.140 |
Why?
|
| Integrins | 1 | 2017 | 81 | 0.140 |
Why?
|
| Nanotubes, Carbon | 1 | 2017 | 19 | 0.140 |
Why?
|
| Receptors, Calcitriol | 1 | 2017 | 70 | 0.140 |
Why?
|
| I-kappa B Kinase | 1 | 2017 | 61 | 0.140 |
Why?
|
| Genes, BRCA2 | 2 | 2011 | 41 | 0.140 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 1997 | 40 | 0.140 |
Why?
|
| Surveys and Questionnaires | 7 | 2024 | 3694 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 1992 | 666 | 0.140 |
Why?
|
| Disease Progression | 7 | 2021 | 2047 | 0.140 |
Why?
|
| Cancer Survivors | 1 | 2020 | 202 | 0.140 |
Why?
|
| Texas | 10 | 2024 | 3583 | 0.140 |
Why?
|
| Paracrine Communication | 1 | 2017 | 69 | 0.140 |
Why?
|
| Weight Loss | 2 | 2020 | 482 | 0.140 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 1997 | 46 | 0.140 |
Why?
|
| Interleukin-1beta | 1 | 2017 | 161 | 0.140 |
Why?
|
| Alopecia | 1 | 2017 | 38 | 0.130 |
Why?
|
| Carcinoma | 4 | 1992 | 286 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-jun | 6 | 2008 | 39 | 0.130 |
Why?
|
| CELF1 Protein | 1 | 2016 | 48 | 0.130 |
Why?
|
| DNA Damage | 2 | 2019 | 513 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2016 | 15 | 0.130 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2016 | 22 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2022 | 539 | 0.130 |
Why?
|
| Syndrome | 2 | 2011 | 1119 | 0.130 |
Why?
|
| Scalp | 1 | 2017 | 57 | 0.130 |
Why?
|
| Methotrexate | 1 | 2018 | 341 | 0.130 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2016 | 58 | 0.130 |
Why?
|
| Amyloid beta-Peptides | 1 | 2018 | 211 | 0.130 |
Why?
|
| Medulloblastoma | 2 | 2018 | 325 | 0.130 |
Why?
|
| Stromal Cells | 2 | 2015 | 299 | 0.130 |
Why?
|
| SOXC Transcription Factors | 1 | 2016 | 9 | 0.130 |
Why?
|
| Down-Regulation | 6 | 2016 | 699 | 0.130 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2016 | 30 | 0.130 |
Why?
|
| Genes, myc | 2 | 2011 | 100 | 0.130 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 257 | 0.130 |
Why?
|
| Doxorubicin | 5 | 2015 | 289 | 0.130 |
Why?
|
| GTP-Binding Protein alpha Subunit, Gi2 | 1 | 2015 | 5 | 0.130 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2016 | 51 | 0.130 |
Why?
|
| Adolescent | 14 | 2024 | 19279 | 0.120 |
Why?
|
| Triazines | 3 | 2010 | 29 | 0.120 |
Why?
|
| E2F1 Transcription Factor | 1 | 2016 | 47 | 0.120 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 2 | 2013 | 35 | 0.120 |
Why?
|
| Reproducibility of Results | 6 | 2020 | 2876 | 0.120 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2016 | 101 | 0.120 |
Why?
|
| Proinsulin | 1 | 2015 | 12 | 0.120 |
Why?
|
| Osteopontin | 2 | 2014 | 48 | 0.120 |
Why?
|
| Hypothermia, Induced | 1 | 2017 | 167 | 0.120 |
Why?
|
| Bone and Bones | 1 | 2017 | 266 | 0.120 |
Why?
|
| Cell Nucleus | 3 | 2020 | 676 | 0.120 |
Why?
|
| Calmodulin | 1 | 2016 | 230 | 0.120 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2017 | 555 | 0.120 |
Why?
|
| Mice, Knockout | 10 | 2015 | 3729 | 0.120 |
Why?
|
| Bone Neoplasms | 3 | 2017 | 419 | 0.120 |
Why?
|
| Risk Factors | 16 | 2019 | 10270 | 0.120 |
Why?
|
| Anthracyclines | 2 | 2017 | 36 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2021 | 173 | 0.120 |
Why?
|
| Fluorouracil | 5 | 2014 | 127 | 0.120 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 429 | 0.120 |
Why?
|
| Multivariate Analysis | 7 | 2012 | 1428 | 0.120 |
Why?
|
| Prospective Studies | 10 | 2023 | 6135 | 0.120 |
Why?
|
| Genes, Regulator | 2 | 2006 | 56 | 0.120 |
Why?
|
| Fibroblasts | 2 | 2016 | 882 | 0.120 |
Why?
|
| Adipose Tissue | 2 | 2015 | 462 | 0.120 |
Why?
|
| GATA2 Transcription Factor | 1 | 2014 | 39 | 0.120 |
Why?
|
| Calcinosis | 1 | 2016 | 176 | 0.120 |
Why?
|
| Proteome | 2 | 2021 | 243 | 0.120 |
Why?
|
| Communication | 1 | 2018 | 507 | 0.110 |
Why?
|
| GTP Phosphohydrolases | 1 | 2015 | 143 | 0.110 |
Why?
|
| BRCA1 Protein | 2 | 2012 | 68 | 0.110 |
Why?
|
| Serine Endopeptidases | 1 | 2015 | 177 | 0.110 |
Why?
|
| Mastectomy, Segmental | 2 | 1994 | 27 | 0.110 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2015 | 71 | 0.110 |
Why?
|
| Integrin beta1 | 2 | 2011 | 53 | 0.110 |
Why?
|
| Securin | 1 | 2014 | 3 | 0.110 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2015 | 137 | 0.110 |
Why?
|
| MAP Kinase Kinase Kinase 3 | 1 | 2014 | 9 | 0.110 |
Why?
|
| Research Report | 1 | 2014 | 75 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 2017 | 811 | 0.110 |
Why?
|
| Veratrum Alkaloids | 2 | 2017 | 11 | 0.110 |
Why?
|
| Mitotic Index | 2 | 1999 | 19 | 0.110 |
Why?
|
| Neuroepithelial Cells | 1 | 2013 | 8 | 0.110 |
Why?
|
| Tissue Distribution | 4 | 2025 | 382 | 0.110 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 2 | 2012 | 37 | 0.110 |
Why?
|
| Oncogenes | 2 | 2013 | 167 | 0.110 |
Why?
|
| DNA-Binding Proteins | 5 | 2019 | 2043 | 0.110 |
Why?
|
| Lung Diseases, Obstructive | 1 | 1993 | 34 | 0.110 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2011 | 93 | 0.110 |
Why?
|
| PPAR gamma | 1 | 2014 | 88 | 0.110 |
Why?
|
| Semaphorins | 1 | 2013 | 30 | 0.110 |
Why?
|
| Decision Making | 3 | 2018 | 655 | 0.110 |
Why?
|
| Receptors, Retinoic Acid | 3 | 2002 | 100 | 0.110 |
Why?
|
| Ultrasonography, Mammary | 1 | 2013 | 28 | 0.110 |
Why?
|
| Insulin Resistance | 2 | 2016 | 637 | 0.110 |
Why?
|
| Patient Selection | 2 | 2015 | 693 | 0.110 |
Why?
|
| Thiazolidinediones | 1 | 2014 | 82 | 0.110 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2013 | 61 | 0.110 |
Why?
|
| Morbidity | 2 | 2000 | 247 | 0.110 |
Why?
|
| Radiology Information Systems | 1 | 2013 | 23 | 0.110 |
Why?
|
| Cell Adhesion | 6 | 2017 | 324 | 0.110 |
Why?
|
| Somatomedins | 3 | 1999 | 36 | 0.100 |
Why?
|
| Cognition | 1 | 2018 | 721 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2015 | 222 | 0.100 |
Why?
|
| Comprehension | 1 | 2013 | 75 | 0.100 |
Why?
|
| Analysis of Variance | 8 | 2009 | 1014 | 0.100 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2014 | 157 | 0.100 |
Why?
|
| Genotype | 3 | 2017 | 2556 | 0.100 |
Why?
|
| Sirolimus | 1 | 2014 | 222 | 0.100 |
Why?
|
| MicroRNAs | 3 | 2015 | 835 | 0.100 |
Why?
|
| Green Fluorescent Proteins | 2 | 2014 | 390 | 0.100 |
Why?
|
| Growth Inhibitors | 2 | 2003 | 38 | 0.100 |
Why?
|
| Cell Differentiation | 5 | 2018 | 1887 | 0.100 |
Why?
|
| Mental Recall | 1 | 2013 | 143 | 0.100 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 320 | 0.100 |
Why?
|
| Carnitine Acyltransferases | 1 | 2012 | 6 | 0.100 |
Why?
|
| Insulin Receptor Substrate Proteins | 3 | 2009 | 78 | 0.100 |
Why?
|
| Child | 14 | 2024 | 24374 | 0.100 |
Why?
|
| Mammaplasty | 1 | 2013 | 53 | 0.100 |
Why?
|
| Risk | 3 | 2011 | 755 | 0.100 |
Why?
|
| Gene Expression Regulation, Developmental | 3 | 2014 | 995 | 0.100 |
Why?
|
| LIM Domain Proteins | 1 | 2012 | 59 | 0.100 |
Why?
|
| Cytokines | 3 | 2013 | 1290 | 0.100 |
Why?
|
| Osteosarcoma | 1 | 2015 | 253 | 0.100 |
Why?
|
| Research | 1 | 2014 | 263 | 0.100 |
Why?
|
| Genes, ras | 3 | 2015 | 99 | 0.100 |
Why?
|
| Doxycycline | 2 | 2014 | 117 | 0.100 |
Why?
|
| Macrophages | 2 | 2015 | 619 | 0.100 |
Why?
|
| Cross-Over Studies | 2 | 2012 | 313 | 0.100 |
Why?
|
| Ubiquitin-Activating Enzymes | 1 | 2011 | 23 | 0.100 |
Why?
|
| Flow Cytometry | 7 | 2014 | 797 | 0.090 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2018 | 780 | 0.090 |
Why?
|
| Phosphoproteins | 3 | 1999 | 402 | 0.090 |
Why?
|
| Heterozygote | 2 | 2011 | 672 | 0.090 |
Why?
|
| Neurogenesis | 1 | 2013 | 189 | 0.090 |
Why?
|
| Costs and Cost Analysis | 2 | 2011 | 164 | 0.090 |
Why?
|
| Oncogene Proteins | 2 | 2010 | 136 | 0.090 |
Why?
|
| Sesquiterpenes | 3 | 2000 | 22 | 0.090 |
Why?
|
| Thoracic Surgery | 1 | 1993 | 161 | 0.090 |
Why?
|
| Biometry | 1 | 1992 | 136 | 0.090 |
Why?
|
| DNA | 2 | 2016 | 1597 | 0.090 |
Why?
|
| Membrane Proteins | 4 | 2013 | 1533 | 0.090 |
Why?
|
| Papillomaviridae | 2 | 2023 | 143 | 0.090 |
Why?
|
| Muscular Diseases | 1 | 2012 | 104 | 0.090 |
Why?
|
| Learning Curve | 1 | 2011 | 53 | 0.090 |
Why?
|
| Guanine Nucleotide Dissociation Inhibitors | 1 | 2011 | 10 | 0.090 |
Why?
|
| Immunoenzyme Techniques | 5 | 2010 | 258 | 0.090 |
Why?
|
| Cadherins | 1 | 2012 | 166 | 0.090 |
Why?
|
| Genes, Dominant | 3 | 2006 | 245 | 0.090 |
Why?
|
| Interleukin-17 | 1 | 2012 | 120 | 0.090 |
Why?
|
| Small Molecule Libraries | 1 | 2012 | 125 | 0.090 |
Why?
|
| Single-Blind Method | 1 | 2011 | 235 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 8 | 2010 | 1003 | 0.090 |
Why?
|
| Th17 Cells | 1 | 2012 | 91 | 0.090 |
Why?
|
| Endometrial Neoplasms | 1 | 1992 | 97 | 0.090 |
Why?
|
| Immunoblotting | 6 | 2011 | 311 | 0.090 |
Why?
|
| Obesity | 2 | 2020 | 2262 | 0.090 |
Why?
|
| Calcium | 1 | 2016 | 1100 | 0.090 |
Why?
|
| Nanoshells | 1 | 2010 | 13 | 0.090 |
Why?
|
| Deoxycytidine | 3 | 2014 | 78 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2015 | 681 | 0.090 |
Why?
|
| N-Acetylneuraminic Acid | 1 | 1990 | 27 | 0.090 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2010 | 47 | 0.090 |
Why?
|
| Polyomavirus | 1 | 2010 | 32 | 0.090 |
Why?
|
| Alzheimer Disease | 1 | 2018 | 799 | 0.090 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 48 | 0.090 |
Why?
|
| Gold | 1 | 2010 | 48 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2011 | 197 | 0.090 |
Why?
|
| Retinoid X Receptors | 3 | 2005 | 33 | 0.090 |
Why?
|
| Drug Delivery Systems | 2 | 2009 | 186 | 0.090 |
Why?
|
| Metabolome | 1 | 2013 | 294 | 0.090 |
Why?
|
| Hyperthermia, Induced | 1 | 2010 | 54 | 0.090 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2010 | 238 | 0.080 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2009 | 3 | 0.080 |
Why?
|
| Lymphoma, Large-Cell, Immunoblastic | 1 | 2009 | 5 | 0.080 |
Why?
|
| Peptide Fragments | 4 | 2008 | 779 | 0.080 |
Why?
|
| Genetic Therapy | 2 | 2025 | 679 | 0.080 |
Why?
|
| Transcriptional Activation | 5 | 2016 | 484 | 0.080 |
Why?
|
| Medicine | 1 | 2011 | 97 | 0.080 |
Why?
|
| Incidence | 8 | 2009 | 3138 | 0.080 |
Why?
|
| Hot Flashes | 1 | 2009 | 6 | 0.080 |
Why?
|
| Child, Preschool | 9 | 2024 | 14009 | 0.080 |
Why?
|
| Hedgehog Proteins | 2 | 2008 | 185 | 0.080 |
Why?
|
| RNA, Neoplasm | 5 | 2009 | 135 | 0.080 |
Why?
|
| Premenopause | 2 | 2001 | 31 | 0.080 |
Why?
|
| Physicians | 2 | 2018 | 581 | 0.080 |
Why?
|
| Plasmids | 3 | 2011 | 510 | 0.080 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2009 | 129 | 0.080 |
Why?
|
| Cell Cycle Proteins | 4 | 2014 | 642 | 0.080 |
Why?
|
| Mesoderm | 1 | 2009 | 109 | 0.080 |
Why?
|
| Microdissection | 1 | 2009 | 12 | 0.080 |
Why?
|
| Nuclear Matrix-Associated Proteins | 1 | 2009 | 24 | 0.080 |
Why?
|
| Private Sector | 1 | 2009 | 24 | 0.080 |
Why?
|
| Matrix Attachment Region Binding Proteins | 1 | 2009 | 19 | 0.080 |
Why?
|
| Sertraline | 1 | 2009 | 44 | 0.080 |
Why?
|
| DNA, Complementary | 2 | 2000 | 461 | 0.080 |
Why?
|
| Drainage | 1 | 2010 | 258 | 0.080 |
Why?
|
| Marketing of Health Services | 1 | 2009 | 25 | 0.080 |
Why?
|
| Neoplasm, Residual | 1 | 2009 | 123 | 0.080 |
Why?
|
| Access to Information | 1 | 2009 | 40 | 0.080 |
Why?
|
| Early Detection of Cancer | 2 | 2023 | 360 | 0.080 |
Why?
|
| Medroxyprogesterone | 1 | 1988 | 8 | 0.080 |
Why?
|
| Shock, Hemorrhagic | 1 | 2009 | 54 | 0.080 |
Why?
|
| Age Factors | 6 | 2013 | 2818 | 0.080 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2009 | 144 | 0.080 |
Why?
|
| Lung | 3 | 2014 | 1491 | 0.080 |
Why?
|
| Education, Medical, Graduate | 1 | 2013 | 518 | 0.070 |
Why?
|
| Registries | 3 | 1999 | 1424 | 0.070 |
Why?
|
| Lasers | 1 | 2009 | 114 | 0.070 |
Why?
|
| Autistic Disorder | 1 | 2011 | 343 | 0.070 |
Why?
|
| Decision Making, Computer-Assisted | 2 | 2002 | 19 | 0.070 |
Why?
|
| Kidney Neoplasms | 2 | 2010 | 433 | 0.070 |
Why?
|
| Nicotinic Acids | 1 | 2007 | 7 | 0.070 |
Why?
|
| Phenotype | 8 | 2014 | 4256 | 0.070 |
Why?
|
| Triazoles | 3 | 2014 | 137 | 0.070 |
Why?
|
| Tissue Adhesives | 1 | 2008 | 36 | 0.070 |
Why?
|
| Environment, Controlled | 1 | 2007 | 8 | 0.070 |
Why?
|
| Enzyme Activation | 4 | 2011 | 622 | 0.070 |
Why?
|
| Fluorophotometry | 1 | 2007 | 30 | 0.070 |
Why?
|
| Drug Screening Assays, Antitumor | 7 | 2000 | 93 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 3 | 1997 | 32 | 0.070 |
Why?
|
| Combined Modality Therapy | 5 | 2014 | 1231 | 0.070 |
Why?
|
| Gene Expression Regulation, Bacterial | 2 | 2006 | 158 | 0.070 |
Why?
|
| Genetic Heterogeneity | 2 | 2006 | 126 | 0.070 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2009 | 572 | 0.070 |
Why?
|
| Case-Control Studies | 5 | 2017 | 3281 | 0.070 |
Why?
|
| Myelopoiesis | 1 | 2007 | 13 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2023 | 420 | 0.070 |
Why?
|
| Brain Mapping | 1 | 2010 | 397 | 0.070 |
Why?
|
| Linear Models | 3 | 2013 | 671 | 0.070 |
Why?
|
| Nerve Tissue Proteins | 1 | 2013 | 1111 | 0.070 |
Why?
|
| Fixatives | 1 | 2007 | 14 | 0.070 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2007 | 5 | 0.070 |
Why?
|
| Fatty Acids | 3 | 2016 | 346 | 0.070 |
Why?
|
| Paraffin Embedding | 1 | 2007 | 33 | 0.070 |
Why?
|
| Cohort Studies | 5 | 2008 | 4795 | 0.070 |
Why?
|
| Formaldehyde | 1 | 2007 | 35 | 0.070 |
Why?
|
| Phenylurea Compounds | 2 | 2015 | 48 | 0.070 |
Why?
|
| DNA Replication | 3 | 2019 | 352 | 0.070 |
Why?
|
| Tissue Fixation | 1 | 2007 | 38 | 0.070 |
Why?
|
| Bacterial Capsules | 2 | 2004 | 37 | 0.070 |
Why?
|
| Counseling | 1 | 2009 | 216 | 0.070 |
Why?
|
| Sulfonamides | 1 | 2009 | 261 | 0.070 |
Why?
|
| Drug Administration Schedule | 6 | 2013 | 721 | 0.070 |
Why?
|
| Myeloid Cells | 1 | 2007 | 101 | 0.070 |
Why?
|
| Smoothened Receptor | 3 | 2015 | 28 | 0.070 |
Why?
|
| Shock | 1 | 2008 | 90 | 0.070 |
Why?
|
| Receptors, Interleukin | 1 | 2006 | 33 | 0.070 |
Why?
|
| Cells, Cultured | 5 | 2018 | 3038 | 0.070 |
Why?
|
| Loss of Heterozygosity | 2 | 2014 | 125 | 0.070 |
Why?
|
| src-Family Kinases | 2 | 2011 | 89 | 0.070 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2024 | 3153 | 0.070 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 2 | 1997 | 54 | 0.070 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2005 | 395 | 0.070 |
Why?
|
| In Vitro Techniques | 5 | 2021 | 969 | 0.070 |
Why?
|
| Genetic Markers | 2 | 2005 | 604 | 0.070 |
Why?
|
| Mass Screening | 2 | 2023 | 782 | 0.060 |
Why?
|
| Membrane Glycoproteins | 2 | 2003 | 409 | 0.060 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2022 | 95 | 0.060 |
Why?
|
| Risk Assessment | 4 | 2011 | 3441 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 8 | 2009 | 1586 | 0.060 |
Why?
|
| Sp1 Transcription Factor | 2 | 2004 | 42 | 0.060 |
Why?
|
| Contrast Media | 1 | 2010 | 471 | 0.060 |
Why?
|
| Virus Latency | 2 | 2015 | 61 | 0.060 |
Why?
|
| Clinical Trials, Phase II as Topic | 2 | 2020 | 71 | 0.060 |
Why?
|
| Cathepsin D | 2 | 1997 | 16 | 0.060 |
Why?
|
| Enterococcus faecalis | 1 | 2006 | 44 | 0.060 |
Why?
|
| Models, Biological | 5 | 2014 | 1459 | 0.060 |
Why?
|
| Patient Education as Topic | 1 | 2009 | 437 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 4 | 2010 | 457 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2005 | 61 | 0.060 |
Why?
|
| Drug Resistance | 6 | 1998 | 257 | 0.060 |
Why?
|
| Wounds and Injuries | 1 | 2009 | 372 | 0.060 |
Why?
|
| Cyclin D1 | 3 | 2011 | 112 | 0.060 |
Why?
|
| Hyperplasia | 4 | 2015 | 208 | 0.060 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2019 | 762 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2022 | 3552 | 0.060 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2004 | 16 | 0.060 |
Why?
|
| Neutrophils | 1 | 2007 | 381 | 0.060 |
Why?
|
| Probability | 4 | 2002 | 320 | 0.060 |
Why?
|
| Biological Specimen Banks | 1 | 2005 | 51 | 0.060 |
Why?
|
| Florida | 4 | 1992 | 78 | 0.060 |
Why?
|
| Serogroup | 1 | 2025 | 59 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 2634 | 0.060 |
Why?
|
| Clinical Competence | 1 | 2011 | 998 | 0.060 |
Why?
|
| Pediatrics | 1 | 2014 | 1164 | 0.060 |
Why?
|
| Gambia | 1 | 2024 | 28 | 0.060 |
Why?
|
| Barrett Esophagus | 1 | 2009 | 340 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2014 | 486 | 0.060 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2021 | 152 | 0.060 |
Why?
|
| Drug Synergism | 4 | 2016 | 228 | 0.060 |
Why?
|
| Smartphone | 1 | 2024 | 37 | 0.060 |
Why?
|
| DNA Probes | 1 | 2004 | 123 | 0.060 |
Why?
|
| Cytological Techniques | 2 | 1995 | 19 | 0.060 |
Why?
|
| Coculture Techniques | 2 | 2015 | 225 | 0.060 |
Why?
|
| Sample Size | 1 | 2004 | 86 | 0.060 |
Why?
|
| Plasma | 2 | 2016 | 98 | 0.060 |
Why?
|
| Diet, High-Fat | 2 | 2016 | 212 | 0.060 |
Why?
|
| Albumins | 1 | 2024 | 89 | 0.050 |
Why?
|
| Epilepsy | 1 | 2011 | 871 | 0.050 |
Why?
|
| Transduction, Genetic | 1 | 2025 | 290 | 0.050 |
Why?
|
| Genes, Neoplasm | 3 | 2011 | 80 | 0.050 |
Why?
|
| Gene Silencing | 3 | 2011 | 235 | 0.050 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 1994 | 16 | 0.050 |
Why?
|
| Antigens, Surface | 2 | 2015 | 119 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2024 | 209 | 0.050 |
Why?
|
| Vaginal Smears | 1 | 2023 | 48 | 0.050 |
Why?
|
| Pyrimidines | 2 | 2017 | 369 | 0.050 |
Why?
|
| Menopause | 3 | 2005 | 75 | 0.050 |
Why?
|
| Homeodomain Proteins | 1 | 2006 | 543 | 0.050 |
Why?
|
| Neoplasms, Second Primary | 1 | 2005 | 153 | 0.050 |
Why?
|
| Obstetric Labor Complications | 1 | 2024 | 92 | 0.050 |
Why?
|
| Germ Cells | 1 | 2024 | 194 | 0.050 |
Why?
|
| NFI Transcription Factors | 1 | 2023 | 50 | 0.050 |
Why?
|
| Muscle, Skeletal | 3 | 2016 | 947 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2023 | 85 | 0.050 |
Why?
|
| Arsenicals | 1 | 2003 | 14 | 0.050 |
Why?
|
| United States | 9 | 2021 | 10887 | 0.050 |
Why?
|
| Oxides | 1 | 2003 | 15 | 0.050 |
Why?
|
| RNA Interference | 2 | 2017 | 498 | 0.050 |
Why?
|
| Gene Knockdown Techniques | 2 | 2014 | 355 | 0.050 |
Why?
|
| Mobile Applications | 1 | 2024 | 89 | 0.050 |
Why?
|
| Membrane Transport Proteins | 2 | 2019 | 176 | 0.050 |
Why?
|
| Interferons | 1 | 2023 | 124 | 0.050 |
Why?
|
| CTLA-4 Antigen | 1 | 2023 | 53 | 0.050 |
Why?
|
| Bacillus anthracis | 1 | 2003 | 40 | 0.050 |
Why?
|
| Mastectomy, Radical | 3 | 2000 | 8 | 0.050 |
Why?
|
| Regression Analysis | 5 | 2013 | 778 | 0.050 |
Why?
|
| Protein Isoforms | 3 | 2011 | 406 | 0.050 |
Why?
|
| Proteins | 1 | 2008 | 1036 | 0.050 |
Why?
|
| Lung Diseases | 2 | 1996 | 383 | 0.050 |
Why?
|
| Laparotomy | 2 | 2008 | 135 | 0.050 |
Why?
|
| Vidarabine | 1 | 2022 | 80 | 0.050 |
Why?
|
| Cytarabine | 1 | 2022 | 98 | 0.050 |
Why?
|
| Sensitivity and Specificity | 5 | 2010 | 2050 | 0.050 |
Why?
|
| Fracture Fixation, Internal | 1 | 2002 | 77 | 0.050 |
Why?
|
| Caspases | 1 | 2003 | 162 | 0.050 |
Why?
|
| Cystoscopy | 1 | 2022 | 44 | 0.050 |
Why?
|
| Self Care | 1 | 2023 | 212 | 0.050 |
Why?
|
| Confidentiality | 2 | 2013 | 99 | 0.050 |
Why?
|
| B7-H1 Antigen | 1 | 2023 | 114 | 0.050 |
Why?
|
| Hysterectomy | 2 | 1995 | 191 | 0.050 |
Why?
|
| Hip Fractures | 1 | 2002 | 61 | 0.050 |
Why?
|
| Amino Acids | 2 | 2016 | 664 | 0.050 |
Why?
|
| Mutagenesis | 2 | 2019 | 346 | 0.050 |
Why?
|
| Infant | 6 | 2024 | 12468 | 0.050 |
Why?
|
| Pregnancy | 4 | 2024 | 7179 | 0.050 |
Why?
|
| Infusions, Intravenous | 5 | 2005 | 547 | 0.050 |
Why?
|
| Nitriles | 2 | 2013 | 146 | 0.050 |
Why?
|
| Colony-Forming Units Assay | 2 | 2014 | 68 | 0.050 |
Why?
|
| Logistic Models | 3 | 2010 | 1805 | 0.050 |
Why?
|
| Rats | 5 | 2009 | 3677 | 0.050 |
Why?
|
| Prenatal Care | 1 | 2024 | 347 | 0.050 |
Why?
|
| Hyaluronan Receptors | 2 | 2013 | 66 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2010 | 802 | 0.050 |
Why?
|
| ROC Curve | 2 | 2015 | 569 | 0.040 |
Why?
|
| Uterus | 1 | 2005 | 569 | 0.040 |
Why?
|
| Dihydrotestosterone | 1 | 2020 | 67 | 0.040 |
Why?
|
| Multiple Myeloma | 2 | 2003 | 169 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 579 | 0.040 |
Why?
|
| Muscle Proteins | 1 | 2003 | 417 | 0.040 |
Why?
|
| Protein Biosynthesis | 2 | 2016 | 663 | 0.040 |
Why?
|
| Chi-Square Distribution | 3 | 2005 | 587 | 0.040 |
Why?
|
| Rural Population | 2 | 2000 | 256 | 0.040 |
Why?
|
| Biopsy | 3 | 2009 | 1237 | 0.040 |
Why?
|
| In Situ Hybridization | 2 | 2005 | 470 | 0.040 |
Why?
|
| Ubiquitin | 1 | 2021 | 141 | 0.040 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2001 | 139 | 0.040 |
Why?
|
| DNA Primers | 4 | 2007 | 657 | 0.040 |
Why?
|
| Spirometry | 2 | 1997 | 74 | 0.040 |
Why?
|
| Tretinoin | 1 | 2000 | 116 | 0.040 |
Why?
|
| Cell Separation | 2 | 2014 | 227 | 0.040 |
Why?
|
| Tacrolimus | 1 | 2000 | 99 | 0.040 |
Why?
|
| Cryptosporidium parvum | 1 | 2000 | 27 | 0.040 |
Why?
|
| Cryptosporidiosis | 1 | 2000 | 41 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 191 | 0.040 |
Why?
|
| Antibodies, Protozoan | 1 | 2000 | 76 | 0.040 |
Why?
|
| Co-Repressor Proteins | 1 | 2020 | 37 | 0.040 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2000 | 44 | 0.040 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2001 | 256 | 0.040 |
Why?
|
| Glucose | 2 | 2016 | 880 | 0.040 |
Why?
|
| Chromosome Aberrations | 2 | 2009 | 616 | 0.040 |
Why?
|
| Liver | 3 | 2016 | 1739 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 68 | 0.040 |
Why?
|
| Carcinogens | 3 | 2008 | 152 | 0.040 |
Why?
|
| Hepatitis Antibodies | 1 | 1999 | 5 | 0.040 |
Why?
|
| Knowledge Bases | 1 | 2019 | 36 | 0.040 |
Why?
|
| Pilot Projects | 3 | 1999 | 1387 | 0.040 |
Why?
|
| Radiography | 1 | 2022 | 821 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2014 | 546 | 0.040 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 2 | 2014 | 23 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2020 | 201 | 0.040 |
Why?
|
| DNA Topoisomerases, Type II | 1 | 1999 | 22 | 0.040 |
Why?
|
| Hepatitis A | 1 | 1999 | 32 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2014 | 541 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1999 | 62 | 0.040 |
Why?
|
| Open Reading Frames | 2 | 2014 | 211 | 0.040 |
Why?
|
| Medically Uninsured | 1 | 2020 | 73 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2024 | 512 | 0.040 |
Why?
|
| Molecular Probe Techniques | 1 | 1999 | 23 | 0.040 |
Why?
|
| G2 Phase | 2 | 2003 | 44 | 0.040 |
Why?
|
| ras Proteins | 1 | 2020 | 137 | 0.040 |
Why?
|
| CD24 Antigen | 2 | 2009 | 29 | 0.040 |
Why?
|
| Folic Acid Antagonists | 1 | 1999 | 16 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 1999 | 100 | 0.040 |
Why?
|
| Benzofurans | 1 | 1999 | 24 | 0.040 |
Why?
|
| Antigens, Neoplasm | 3 | 2005 | 386 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2005 | 90 | 0.040 |
Why?
|
| Anthropometry | 1 | 1999 | 199 | 0.040 |
Why?
|
| Glutamates | 1 | 1999 | 68 | 0.040 |
Why?
|
| Chromosomal Instability | 1 | 2019 | 57 | 0.040 |
Why?
|
| Guanine | 1 | 1999 | 61 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2021 | 744 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 2 | 2010 | 240 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 165 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 2 | 1996 | 68 | 0.040 |
Why?
|
| Candidiasis, Oral | 1 | 1998 | 2 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 2 | 2011 | 310 | 0.040 |
Why?
|
| Pimozide | 1 | 2018 | 6 | 0.040 |
Why?
|
| Remission Induction | 1 | 2019 | 299 | 0.040 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 866 | 0.040 |
Why?
|
| Mammals | 1 | 2019 | 256 | 0.040 |
Why?
|
| Oropharynx | 1 | 1998 | 34 | 0.040 |
Why?
|
| Molecular Sequence Data | 6 | 2004 | 3878 | 0.040 |
Why?
|
| Fluconazole | 1 | 1998 | 47 | 0.040 |
Why?
|
| Recurrence | 4 | 2012 | 1420 | 0.040 |
Why?
|
| Hyperprolactinemia | 1 | 2018 | 23 | 0.040 |
Why?
|
| Phthalimides | 1 | 1998 | 2 | 0.040 |
Why?
|
| Professional-Family Relations | 1 | 2018 | 92 | 0.040 |
Why?
|
| Solubility | 1 | 2018 | 135 | 0.040 |
Why?
|
| Colonic Neoplasms | 2 | 1999 | 246 | 0.040 |
Why?
|
| Length of Stay | 2 | 2011 | 1310 | 0.040 |
Why?
|
| Rats, Inbred WF | 3 | 2002 | 21 | 0.040 |
Why?
|
| Methylnitrosourea | 3 | 2002 | 18 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 307 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 673 | 0.040 |
Why?
|
| NIH 3T3 Cells | 2 | 2010 | 92 | 0.040 |
Why?
|
| Cross-Sectional Studies | 2 | 2024 | 3424 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2014 | 82 | 0.040 |
Why?
|
| Chorioallantoic Membrane | 1 | 2017 | 12 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 2 | 2011 | 15 | 0.040 |
Why?
|
| Plaque, Amyloid | 1 | 2018 | 64 | 0.040 |
Why?
|
| Photoreceptor Cells | 1 | 1998 | 91 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2018 | 120 | 0.040 |
Why?
|
| Patients | 1 | 2018 | 118 | 0.040 |
Why?
|
| Risperidone | 1 | 2018 | 59 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 1998 | 136 | 0.040 |
Why?
|
| Androstadienes | 1 | 2017 | 49 | 0.040 |
Why?
|
| Chick Embryo | 1 | 2017 | 131 | 0.040 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 127 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2013 | 455 | 0.040 |
Why?
|
| Genes, Reporter | 2 | 2014 | 381 | 0.040 |
Why?
|
| Alleles | 2 | 2017 | 1615 | 0.040 |
Why?
|
| Hydroxyurea | 1 | 1998 | 82 | 0.040 |
Why?
|
| Virus Activation | 1 | 1998 | 87 | 0.030 |
Why?
|
| Genomic Instability | 1 | 2019 | 228 | 0.030 |
Why?
|
| Pharmacogenomic Variants | 1 | 2017 | 35 | 0.030 |
Why?
|
| Mitosis | 2 | 2011 | 235 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2017 | 16 | 0.030 |
Why?
|
| Bridged-Ring Compounds | 1 | 2017 | 17 | 0.030 |
Why?
|
| Genes, cdc | 1 | 1997 | 25 | 0.030 |
Why?
|
| Flutamide | 1 | 1997 | 26 | 0.030 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2009 | 64 | 0.030 |
Why?
|
| Retinal Degeneration | 1 | 1998 | 93 | 0.030 |
Why?
|
| Telomerase | 1 | 1997 | 160 | 0.030 |
Why?
|
| Cytosol | 1 | 1997 | 161 | 0.030 |
Why?
|
| Cyclins | 1 | 1997 | 101 | 0.030 |
Why?
|
| Protein Binding | 2 | 2017 | 1738 | 0.030 |
Why?
|
| Salivary Gland Neoplasms | 1 | 1997 | 55 | 0.030 |
Why?
|
| Administration, Oral | 3 | 2000 | 680 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 2 | 1993 | 25 | 0.030 |
Why?
|
| Postmenopause | 1 | 1997 | 126 | 0.030 |
Why?
|
| Congenital Abnormalities | 1 | 1999 | 254 | 0.030 |
Why?
|
| Ovariectomy | 2 | 2008 | 183 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2000 | 647 | 0.030 |
Why?
|
| Cell Line | 4 | 2007 | 2749 | 0.030 |
Why?
|
| Lysosomes | 1 | 2018 | 236 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1999 | 647 | 0.030 |
Why?
|
| Temporomandibular Joint Dysfunction Syndrome | 1 | 1996 | 2 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 1997 | 210 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2013 | 429 | 0.030 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 1996 | 10 | 0.030 |
Why?
|
| Maximum Tolerated Dose | 1 | 2016 | 158 | 0.030 |
Why?
|
| Malocclusion, Angle Class II | 1 | 1996 | 3 | 0.030 |
Why?
|
| Receptor, Insulin | 2 | 2010 | 67 | 0.030 |
Why?
|
| Tumor Virus Infections | 1 | 1997 | 135 | 0.030 |
Why?
|
| Telomere | 1 | 1997 | 213 | 0.030 |
Why?
|
| Cyclophosphamide | 2 | 2010 | 418 | 0.030 |
Why?
|
| Vitamin D | 1 | 2017 | 161 | 0.030 |
Why?
|
| Hospital Costs | 1 | 1997 | 179 | 0.030 |
Why?
|
| Etoposide | 2 | 2014 | 114 | 0.030 |
Why?
|
| Polyethylene Glycols | 1 | 1997 | 225 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 1998 | 288 | 0.030 |
Why?
|
| Drosophila | 2 | 2015 | 779 | 0.030 |
Why?
|
| Cyclin-Dependent Kinases | 1 | 2016 | 86 | 0.030 |
Why?
|
| Primary Prevention | 1 | 2017 | 171 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2019 | 476 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2018 | 493 | 0.030 |
Why?
|
| Mammography | 1 | 2016 | 114 | 0.030 |
Why?
|
| Bias | 1 | 1996 | 131 | 0.030 |
Why?
|
| Receptors, Calcitonin | 1 | 1995 | 21 | 0.030 |
Why?
|
| Axons | 1 | 2018 | 377 | 0.030 |
Why?
|
| Cell Self Renewal | 1 | 2015 | 43 | 0.030 |
Why?
|
| Transforming Growth Factor alpha | 1 | 1994 | 27 | 0.030 |
Why?
|
| Endoplasmic Reticulum | 1 | 2016 | 217 | 0.030 |
Why?
|
| Capecitabine | 1 | 2014 | 16 | 0.030 |
Why?
|
| Calcitonin | 1 | 1995 | 30 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 396 | 0.030 |
Why?
|
| Preoperative Care | 1 | 1997 | 354 | 0.030 |
Why?
|
| Physician-Patient Relations | 1 | 2018 | 429 | 0.030 |
Why?
|
| Retinoids | 2 | 2006 | 34 | 0.030 |
Why?
|
| Base Sequence | 5 | 2002 | 3090 | 0.030 |
Why?
|
| Retina | 1 | 1998 | 450 | 0.030 |
Why?
|
| Organoids | 1 | 2017 | 282 | 0.030 |
Why?
|
| Osteoclasts | 1 | 1995 | 55 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 1998 | 676 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2018 | 361 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 1994 | 75 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2014 | 57 | 0.030 |
Why?
|
| Fluorescence | 1 | 2014 | 95 | 0.030 |
Why?
|
| Crosses, Genetic | 2 | 2009 | 163 | 0.030 |
Why?
|
| Insulin-Secreting Cells | 1 | 2016 | 149 | 0.030 |
Why?
|
| Retroviridae | 1 | 2015 | 198 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2018 | 1162 | 0.030 |
Why?
|
| Salvage Therapy | 1 | 1996 | 192 | 0.030 |
Why?
|
| Synapses | 1 | 2018 | 455 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 1996 | 348 | 0.030 |
Why?
|
| Lentivirus | 1 | 2014 | 82 | 0.030 |
Why?
|
| Heart Diseases | 2 | 1996 | 490 | 0.030 |
Why?
|
| Topotecan | 3 | 2000 | 48 | 0.030 |
Why?
|
| Virion | 1 | 2015 | 147 | 0.030 |
Why?
|
| Collagen | 1 | 2015 | 315 | 0.030 |
Why?
|
| Random Allocation | 2 | 2011 | 436 | 0.030 |
Why?
|
| Allografts | 1 | 2015 | 191 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 351 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2015 | 330 | 0.030 |
Why?
|
| Inflammation | 2 | 2015 | 1431 | 0.030 |
Why?
|
| Mice, Mutant Strains | 2 | 2009 | 383 | 0.030 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1993 | 14 | 0.030 |
Why?
|
| Hospitals, Military | 1 | 1993 | 10 | 0.030 |
Why?
|
| Quality of Life | 2 | 2017 | 1916 | 0.030 |
Why?
|
| Azepines | 1 | 2014 | 62 | 0.030 |
Why?
|
| Chromatids | 1 | 2014 | 43 | 0.030 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2014 | 35 | 0.030 |
Why?
|
| Seminal Vesicles | 1 | 2013 | 55 | 0.030 |
Why?
|
| Proteolysis | 1 | 2014 | 171 | 0.030 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2014 | 151 | 0.030 |
Why?
|
| Conjunctiva | 1 | 1995 | 197 | 0.030 |
Why?
|
| Mexico | 3 | 2000 | 182 | 0.030 |
Why?
|
| Epigenomics | 1 | 2014 | 163 | 0.030 |
Why?
|
| Escherichia coli | 1 | 2019 | 985 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2000 | 831 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 1993 | 105 | 0.030 |
Why?
|
| Epidemiologic Factors | 1 | 2013 | 8 | 0.030 |
Why?
|
| Blood Proteins | 1 | 1993 | 124 | 0.030 |
Why?
|
| Integrin alpha6 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Pyrroles | 1 | 2014 | 177 | 0.030 |
Why?
|
| Epithelium | 2 | 2009 | 362 | 0.030 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2014 | 294 | 0.030 |
Why?
|
| Hospitals, Public | 1 | 2013 | 42 | 0.030 |
Why?
|
| AC133 Antigen | 1 | 2013 | 35 | 0.030 |
Why?
|
| Binding Sites | 1 | 2016 | 1295 | 0.030 |
Why?
|
| Personal Satisfaction | 1 | 2013 | 101 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 279 | 0.030 |
Why?
|
| Genome-Wide Association Study | 2 | 2011 | 1684 | 0.030 |
Why?
|
| Ploidies | 1 | 2012 | 37 | 0.030 |
Why?
|
| Axilla | 3 | 1999 | 38 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2009 | 1231 | 0.030 |
Why?
|
| Cell Nucleolus | 1 | 2012 | 55 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2013 | 124 | 0.020 |
Why?
|
| Peritoneal Cavity | 1 | 1992 | 19 | 0.020 |
Why?
|
| Ketosis | 1 | 2012 | 15 | 0.020 |
Why?
|
| Phospholipid Ethers | 1 | 1992 | 8 | 0.020 |
Why?
|
| Mammary Glands, Human | 1 | 2013 | 79 | 0.020 |
Why?
|
| Protein Kinases | 2 | 2008 | 332 | 0.020 |
Why?
|
| Odds Ratio | 2 | 2011 | 1254 | 0.020 |
Why?
|
| Interviews as Topic | 1 | 2013 | 372 | 0.020 |
Why?
|
| Diphenhydramine | 1 | 1992 | 10 | 0.020 |
Why?
|
| Droperidol | 1 | 1992 | 3 | 0.020 |
Why?
|
| Alkaloids | 1 | 1992 | 35 | 0.020 |
Why?
|
| Antigens, CD1 | 1 | 2012 | 21 | 0.020 |
Why?
|
| Metoclopramide | 1 | 1992 | 10 | 0.020 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 2002 | 57 | 0.020 |
Why?
|
| Lorazepam | 1 | 1992 | 12 | 0.020 |
Why?
|
| Point Mutation | 1 | 1993 | 346 | 0.020 |
Why?
|
| Receptor, ErbB-3 | 1 | 2011 | 17 | 0.020 |
Why?
|
| Menstrual Cycle | 1 | 1992 | 34 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 1 | 1 | 2013 | 241 | 0.020 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 2004 | 69 | 0.020 |
Why?
|
| Hyperammonemia | 1 | 2012 | 62 | 0.020 |
Why?
|
| Insurance Coverage | 1 | 2013 | 122 | 0.020 |
Why?
|
| Antiemetics | 1 | 1992 | 22 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 371 | 0.020 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2011 | 24 | 0.020 |
Why?
|
| Interleukin-1 | 1 | 1992 | 142 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2010 | 579 | 0.020 |
Why?
|
| Spindle Apparatus | 1 | 2011 | 63 | 0.020 |
Why?
|
| Oncogene Protein v-akt | 1 | 2011 | 30 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2012 | 230 | 0.020 |
Why?
|
| Sumoylation | 1 | 2011 | 35 | 0.020 |
Why?
|
| Vulnerable Populations | 1 | 2013 | 140 | 0.020 |
Why?
|
| Pancreatic Diseases | 1 | 2011 | 38 | 0.020 |
Why?
|
| Cefoxitin | 1 | 1991 | 5 | 0.020 |
Why?
|
| Avian Leukosis Virus | 1 | 2011 | 14 | 0.020 |
Why?
|
| Blood Cells | 2 | 1988 | 49 | 0.020 |
Why?
|
| rho-Specific Guanine Nucleotide Dissociation Inhibitors | 1 | 2011 | 8 | 0.020 |
Why?
|
| Antigen-Presenting Cells | 1 | 2012 | 118 | 0.020 |
Why?
|
| Gene Dosage | 2 | 2008 | 439 | 0.020 |
Why?
|
| Hypoglycemic Agents | 1 | 2015 | 442 | 0.020 |
Why?
|
| rho Guanine Nucleotide Dissociation Inhibitor alpha | 1 | 2011 | 10 | 0.020 |
Why?
|
| Nuclear Receptor Coactivator 2 | 1 | 2013 | 203 | 0.020 |
Why?
|
| Chromatin | 1 | 2014 | 550 | 0.020 |
Why?
|
| Elective Surgical Procedures | 3 | 1997 | 159 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2012 | 440 | 0.020 |
Why?
|
| Dendritic Cells | 1 | 2014 | 409 | 0.020 |
Why?
|
| Gene Order | 1 | 2011 | 79 | 0.020 |
Why?
|
| Gene Deletion | 2 | 2006 | 790 | 0.020 |
Why?
|
| CpG Islands | 1 | 2012 | 323 | 0.020 |
Why?
|
| Cell-Matrix Junctions | 1 | 2010 | 8 | 0.020 |
Why?
|
| Insulin | 1 | 2016 | 1202 | 0.020 |
Why?
|
| Radiation, Ionizing | 1 | 2010 | 41 | 0.020 |
Why?
|
| Pedigree | 2 | 2006 | 1605 | 0.020 |
Why?
|
| Antigens, CD | 1 | 2013 | 420 | 0.020 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2010 | 31 | 0.020 |
Why?
|
| Antigens, Tumor-Associated, Carbohydrate | 1 | 1990 | 12 | 0.020 |
Why?
|
| Amylases | 1 | 2010 | 26 | 0.020 |
Why?
|
| Sialic Acids | 1 | 1990 | 20 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2011 | 154 | 0.020 |
Why?
|
| Epirubicin | 1 | 2010 | 5 | 0.020 |
Why?
|
| Immunoprecipitation | 1 | 2011 | 198 | 0.020 |
Why?
|
| Recombinant Proteins | 3 | 2005 | 1390 | 0.020 |
Why?
|
| Educational Measurement | 1 | 2013 | 324 | 0.020 |
Why?
|
| Polyribosomes | 1 | 2010 | 25 | 0.020 |
Why?
|
| rhoA GTP-Binding Protein | 1 | 2010 | 43 | 0.020 |
Why?
|
| Hypoglycemia | 1 | 2012 | 191 | 0.020 |
Why?
|
| rho GTP-Binding Proteins | 1 | 2011 | 67 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2013 | 368 | 0.020 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2010 | 66 | 0.020 |
Why?
|
| Pyridones | 1 | 2011 | 110 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2011 | 132 | 0.020 |
Why?
|
| Dexamethasone | 1 | 1992 | 276 | 0.020 |
Why?
|
| Hormones | 2 | 1988 | 186 | 0.020 |
Why?
|
| RNA-Binding Proteins | 1 | 2014 | 573 | 0.020 |
Why?
|
| Antibodies | 1 | 2011 | 373 | 0.020 |
Why?
|
| Leukemia | 1 | 1993 | 369 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2009 | 63 | 0.020 |
Why?
|
| Prevalence | 3 | 2002 | 2445 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2009 | 50 | 0.020 |
Why?
|
| Claudin-1 | 1 | 2009 | 20 | 0.020 |
Why?
|
| Quality Control | 1 | 1990 | 119 | 0.020 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2009 | 39 | 0.020 |
Why?
|
| Cytoplasm | 1 | 2010 | 290 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1990 | 71 | 0.020 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2010 | 131 | 0.020 |
Why?
|
| Thrombospondin 1 | 1 | 2009 | 23 | 0.020 |
Why?
|
| Protein Phosphatase 2C | 1 | 2009 | 54 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 319 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2011 | 309 | 0.020 |
Why?
|
| Interferon-gamma | 1 | 2012 | 502 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 1990 | 183 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2011 | 217 | 0.020 |
Why?
|
| Peptides | 1 | 2013 | 796 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2011 | 219 | 0.020 |
Why?
|
| Lipid Metabolism | 1 | 2012 | 356 | 0.020 |
Why?
|
| Epiregulin | 1 | 2009 | 3 | 0.020 |
Why?
|
| G-Quadruplexes | 1 | 2009 | 10 | 0.020 |
Why?
|
| Celecoxib | 1 | 2009 | 32 | 0.020 |
Why?
|
| Microfilament Proteins | 2 | 2003 | 273 | 0.020 |
Why?
|
| Canada | 1 | 1990 | 288 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 1990 | 164 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2011 | 409 | 0.020 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2009 | 115 | 0.020 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2011 | 357 | 0.020 |
Why?
|
| beta Catenin | 1 | 2010 | 202 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 811 | 0.020 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2009 | 135 | 0.020 |
Why?
|
| Image Enhancement | 1 | 2010 | 163 | 0.020 |
Why?
|
| Sampling Studies | 1 | 1988 | 77 | 0.020 |
Why?
|
| Hematopoietic System | 1 | 1988 | 7 | 0.020 |
Why?
|
| Kinetics | 2 | 2003 | 1322 | 0.020 |
Why?
|
| Parity | 1 | 2008 | 78 | 0.020 |
Why?
|
| Imidazoles | 1 | 2009 | 194 | 0.020 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 1988 | 16 | 0.020 |
Why?
|
| Histiocytes | 1 | 1988 | 23 | 0.020 |
Why?
|
| Cell Transplantation | 1 | 2008 | 45 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2009 | 184 | 0.020 |
Why?
|
| Nucleotidyltransferases | 1 | 2008 | 44 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2009 | 121 | 0.020 |
Why?
|
| Binding, Competitive | 1 | 2008 | 185 | 0.020 |
Why?
|
| Principal Component Analysis | 1 | 2009 | 142 | 0.020 |
Why?
|
| Pancreaticojejunostomy | 1 | 2008 | 6 | 0.020 |
Why?
|
| Genetic Variation | 1 | 1995 | 1497 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1991 | 309 | 0.020 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 1992 | 350 | 0.020 |
Why?
|
| Pregnancy, Animal | 1 | 2008 | 76 | 0.020 |
Why?
|
| Hypovolemia | 1 | 2008 | 11 | 0.020 |
Why?
|
| Pulmonary Alveoli | 1 | 2009 | 135 | 0.020 |
Why?
|
| Interleukin-2 | 1 | 1988 | 227 | 0.020 |
Why?
|
| Comorbidity | 1 | 2013 | 1529 | 0.020 |
Why?
|
| Postoperative Care | 1 | 1990 | 298 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 2 | 2003 | 60 | 0.020 |
Why?
|
| Esophagoscopy | 1 | 2009 | 156 | 0.020 |
Why?
|
| Stomach Neoplasms | 1 | 1994 | 545 | 0.020 |
Why?
|
| Unnecessary Procedures | 1 | 2008 | 59 | 0.020 |
Why?
|
| Myocardium | 1 | 2013 | 997 | 0.020 |
Why?
|
| Reactive Oxygen Species | 1 | 2010 | 485 | 0.020 |
Why?
|
| Phagocytosis | 1 | 1988 | 171 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2009 | 461 | 0.020 |
Why?
|
| Patched Receptors | 1 | 2007 | 26 | 0.020 |
Why?
|
| Patched-1 Receptor | 1 | 2007 | 34 | 0.020 |
Why?
|
| Lipids | 1 | 1990 | 514 | 0.020 |
Why?
|
| Choline Dehydrogenase | 1 | 2006 | 2 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2013 | 1561 | 0.020 |
Why?
|
| Receptors, Interleukin-17 | 1 | 2006 | 6 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2007 | 132 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2008 | 230 | 0.020 |
Why?
|
| United Kingdom | 1 | 2007 | 189 | 0.020 |
Why?
|
| Dual Specificity Phosphatase 6 | 1 | 2006 | 2 | 0.020 |
Why?
|
| Resuscitation | 1 | 2009 | 250 | 0.020 |
Why?
|
| Homozygote | 1 | 2008 | 548 | 0.020 |
Why?
|
| RNA, Bacterial | 1 | 2006 | 54 | 0.020 |
Why?
|
| Clone Cells | 2 | 1999 | 166 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2008 | 453 | 0.020 |
Why?
|
| Metabolism | 1 | 2006 | 42 | 0.020 |
Why?
|
| HIV-1 | 1 | 2009 | 465 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2011 | 949 | 0.020 |
Why?
|
| DNA, Antisense | 1 | 2005 | 8 | 0.020 |
Why?
|
| Neuregulin-1 | 1 | 2005 | 13 | 0.020 |
Why?
|
| Aneuploidy | 2 | 1997 | 152 | 0.020 |
Why?
|
| Drug Resistance, Multiple | 1 | 2005 | 48 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 125 | 0.020 |
Why?
|
| Genes, Homeobox | 1 | 2005 | 70 | 0.020 |
Why?
|
| Dimerization | 1 | 2005 | 144 | 0.020 |
Why?
|
| Retinoic Acid 4-Hydroxylase | 1 | 2005 | 6 | 0.020 |
Why?
|
| Cholesterol | 1 | 2008 | 537 | 0.020 |
Why?
|
| Biofilms | 1 | 2006 | 92 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 1637 | 0.020 |
Why?
|
| Drosophila melanogaster | 1 | 2010 | 770 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 2004 | 2705 | 0.010 |
Why?
|
| Enzymes | 1 | 2005 | 52 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 1269 | 0.010 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2005 | 52 | 0.010 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2005 | 61 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2005 | 87 | 0.010 |
Why?
|
| Ethics, Research | 1 | 2005 | 51 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2005 | 292 | 0.010 |
Why?
|
| Luciferases | 1 | 2004 | 132 | 0.010 |
Why?
|
| Neovascularization, Physiologic | 1 | 2005 | 209 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2005 | 158 | 0.010 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2005 | 134 | 0.010 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2004 | 237 | 0.010 |
Why?
|
| Patient Care Planning | 1 | 2005 | 120 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2004 | 275 | 0.010 |
Why?
|
| Multigene Family | 1 | 2004 | 298 | 0.010 |
Why?
|
| Ligands | 1 | 2005 | 532 | 0.010 |
Why?
|
| Integrases | 1 | 2004 | 158 | 0.010 |
Why?
|
| Caspase 8 | 1 | 2003 | 22 | 0.010 |
Why?
|
| Myocytes, Cardiac | 1 | 2008 | 602 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2003 | 40 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2002 | 22 | 0.010 |
Why?
|
| Acetyltransferases | 1 | 2003 | 90 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1994 | 342 | 0.010 |
Why?
|
| Sp3 Transcription Factor | 1 | 2002 | 7 | 0.010 |
Why?
|
| Cloning, Molecular | 2 | 1995 | 891 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 231 | 0.010 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2002 | 49 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2004 | 759 | 0.010 |
Why?
|
| G1 Phase | 1 | 2003 | 67 | 0.010 |
Why?
|
| Carbon Dioxide | 1 | 2004 | 274 | 0.010 |
Why?
|
| Virulence | 1 | 2003 | 262 | 0.010 |
Why?
|
| Caspase 9 | 1 | 2003 | 75 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2008 | 495 | 0.010 |
Why?
|
| Growth Substances | 1 | 2002 | 113 | 0.010 |
Why?
|
| Injections, Intralesional | 1 | 2002 | 46 | 0.010 |
Why?
|
| Benzoates | 1 | 2002 | 20 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2004 | 347 | 0.010 |
Why?
|
| Respiratory Tract Diseases | 1 | 2002 | 75 | 0.010 |
Why?
|
| Thymidine Kinase | 1 | 2002 | 95 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2010 | 2891 | 0.010 |
Why?
|
| Genetic Carrier Screening | 1 | 2002 | 68 | 0.010 |
Why?
|
| beta-Galactosidase | 1 | 2002 | 145 | 0.010 |
Why?
|
| Ganciclovir | 1 | 2002 | 103 | 0.010 |
Why?
|
| Reproductive History | 1 | 2001 | 10 | 0.010 |
Why?
|
| Histone Acetyltransferases | 1 | 2003 | 314 | 0.010 |
Why?
|
| Medical Records | 1 | 2002 | 189 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2001 | 60 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-yes | 1 | 2001 | 3 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 2001 | 307 | 0.010 |
Why?
|
| Liver Neoplasms | 2 | 1988 | 1312 | 0.010 |
Why?
|
| RNA | 1 | 2004 | 570 | 0.010 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2000 | 79 | 0.010 |
Why?
|
| Brain | 1 | 2013 | 2983 | 0.010 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2000 | 43 | 0.010 |
Why?
|
| Lipid Peroxidation | 1 | 2000 | 87 | 0.010 |
Why?
|
| Food Deprivation | 1 | 2000 | 32 | 0.010 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2000 | 77 | 0.010 |
Why?
|
| Antigens, Polyomavirus Transforming | 1 | 2000 | 88 | 0.010 |
Why?
|
| Superoxide Dismutase | 1 | 2000 | 137 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2000 | 260 | 0.010 |
Why?
|
| Glutathione Transferase | 1 | 2000 | 153 | 0.010 |
Why?
|
| Bone Marrow | 2 | 1995 | 324 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2008 | 2091 | 0.010 |
Why?
|
| Software | 1 | 2004 | 683 | 0.010 |
Why?
|
| Hepatitis A Antibodies | 1 | 1999 | 9 | 0.010 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 1999 | 8 | 0.010 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 1999 | 15 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 1999 | 54 | 0.010 |
Why?
|
| Receptors, Somatomedin | 1 | 1999 | 25 | 0.010 |
Why?
|
| HT29 Cells | 1 | 1999 | 44 | 0.010 |
Why?
|
| Adenoviridae | 1 | 2002 | 606 | 0.010 |
Why?
|
| Pemetrexed | 1 | 1999 | 9 | 0.010 |
Why?
|
| Sarcoma, Ewing | 1 | 2000 | 107 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2001 | 793 | 0.010 |
Why?
|
| Carboplatin | 1 | 1999 | 76 | 0.010 |
Why?
|
| Urban Population | 1 | 2000 | 225 | 0.010 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 1999 | 118 | 0.010 |
Why?
|
| Isoenzymes | 1 | 1999 | 229 | 0.010 |
Why?
|
| Histones | 1 | 2002 | 526 | 0.010 |
Why?
|
| Molecular Chaperones | 1 | 1999 | 167 | 0.010 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 193 | 0.010 |
Why?
|
| Hepatitis B | 1 | 1999 | 159 | 0.010 |
Why?
|
| Half-Life | 1 | 1998 | 158 | 0.010 |
Why?
|
| Nuclear Receptor Co-Repressor 1 | 1 | 1998 | 54 | 0.010 |
Why?
|
| Anorexia | 1 | 1998 | 27 | 0.010 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 1998 | 144 | 0.010 |
Why?
|
| Butyrates | 1 | 1998 | 35 | 0.010 |
Why?
|
| Nausea | 1 | 1998 | 83 | 0.010 |
Why?
|
| Birth Weight | 1 | 1999 | 346 | 0.010 |
Why?
|
| Energy Intake | 1 | 2000 | 493 | 0.010 |
Why?
|
| Rhabdomyosarcoma | 1 | 2000 | 190 | 0.010 |
Why?
|
| Utilization Review | 1 | 1997 | 40 | 0.010 |
Why?
|
| Intestinal Absorption | 1 | 1998 | 190 | 0.010 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 1997 | 33 | 0.010 |
Why?
|
| Hospitals, University | 1 | 1997 | 95 | 0.010 |
Why?
|
| Hospitals, Urban | 1 | 1997 | 99 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2002 | 748 | 0.010 |
Why?
|
| Ascites | 1 | 1997 | 88 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1999 | 1079 | 0.010 |
Why?
|
| Immunoradiometric Assay | 1 | 1996 | 3 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 1998 | 326 | 0.010 |
Why?
|
| Densitometry | 1 | 1996 | 25 | 0.010 |
Why?
|
| Autoradiography | 1 | 1996 | 69 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 1997 | 186 | 0.010 |
Why?
|
| Loperamide | 1 | 1996 | 8 | 0.010 |
Why?
|
| Neutropenia | 1 | 1998 | 200 | 0.010 |
Why?
|
| Antidiarrheals | 1 | 1996 | 17 | 0.010 |
Why?
|
| Graft vs Host Disease | 1 | 2000 | 542 | 0.010 |
Why?
|
| Orthodontics, Corrective | 1 | 1996 | 2 | 0.010 |
Why?
|
| Health Expenditures | 1 | 1997 | 102 | 0.010 |
Why?
|
| Mandibular Advancement | 1 | 1996 | 6 | 0.010 |
Why?
|
| Cephalometry | 1 | 1996 | 33 | 0.010 |
Why?
|
| Antigens, Viral | 1 | 1998 | 439 | 0.010 |
Why?
|
| Respiratory Function Tests | 1 | 1996 | 199 | 0.010 |
Why?
|
| Metaphase | 1 | 1995 | 45 | 0.010 |
Why?
|
| Micropore Filters | 1 | 1995 | 7 | 0.010 |
Why?
|
| Range of Motion, Articular | 1 | 1996 | 74 | 0.010 |
Why?
|
| Cellulose | 1 | 1995 | 19 | 0.010 |
Why?
|
| Hepatitis C | 1 | 1999 | 366 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1995 | 153 | 0.010 |
Why?
|
| Neuroblastoma | 1 | 2000 | 520 | 0.010 |
Why?
|
| Hospitals, Veterans | 1 | 1997 | 359 | 0.010 |
Why?
|
| Metallothionein | 1 | 1994 | 14 | 0.010 |
Why?
|
| Culture Media, Conditioned | 1 | 1994 | 80 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1996 | 303 | 0.010 |
Why?
|
| Calcitriol | 1 | 1995 | 80 | 0.010 |
Why?
|
| Rabbits | 1 | 1995 | 709 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1994 | 43 | 0.010 |
Why?
|
| Stimulation, Chemical | 1 | 1994 | 65 | 0.010 |
Why?
|
| Isomerism | 1 | 1994 | 31 | 0.010 |
Why?
|
| Diarrhea | 1 | 1996 | 317 | 0.010 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 1993 | 20 | 0.010 |
Why?
|
| Least-Squares Analysis | 1 | 1993 | 31 | 0.010 |
Why?
|
| Codon | 1 | 1994 | 97 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 1993 | 152 | 0.010 |
Why?
|
| Medicare | 1 | 1997 | 424 | 0.010 |
Why?
|
| Body Weight | 1 | 1998 | 996 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1995 | 259 | 0.010 |
Why?
|
| Oligonucleotides, Antisense | 1 | 1993 | 78 | 0.010 |
Why?
|
| Genome | 1 | 1995 | 472 | 0.010 |
Why?
|
| Monocytes | 1 | 1995 | 351 | 0.010 |
Why?
|
| Carcinoma, Small Cell | 1 | 1992 | 51 | 0.010 |
Why?
|
| Deamination | 1 | 1992 | 2 | 0.010 |
Why?
|
| Tetrahydrouridine | 1 | 1992 | 2 | 0.010 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2000 | 1198 | 0.010 |
Why?
|
| Exons | 1 | 1994 | 796 | 0.010 |
Why?
|
| Pentoxifylline | 1 | 1990 | 20 | 0.010 |
Why?
|
| Benzamides | 1 | 1990 | 105 | 0.010 |
Why?
|
| Caffeine | 1 | 1990 | 70 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2002 | 1947 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 1990 | 282 | 0.010 |
Why?
|
| Oxygen | 1 | 1993 | 553 | 0.000 |
Why?
|
| Alcohol Drinking | 1 | 1991 | 343 | 0.000 |
Why?
|
| Vaccinia virus | 1 | 1988 | 52 | 0.000 |
Why?
|
| Surgical Wound Infection | 1 | 1991 | 260 | 0.000 |
Why?
|
| Histiocytic Sarcoma | 1 | 1988 | 4 | 0.000 |
Why?
|
| Transfusion Reaction | 1 | 1988 | 42 | 0.000 |
Why?
|
| Sex Factors | 1 | 1991 | 1280 | 0.000 |
Why?
|
| Spleen | 1 | 1988 | 280 | 0.000 |
Why?
|
| Haiti | 1 | 1987 | 11 | 0.000 |
Why?
|
| Nasopharyngeal Neoplasms | 1 | 1987 | 57 | 0.000 |
Why?
|
| Surgical Procedures, Operative | 1 | 1988 | 183 | 0.000 |
Why?
|
| Viral Vaccines | 1 | 1988 | 333 | 0.000 |
Why?
|
| Sarcoma, Kaposi | 1 | 1987 | 119 | 0.000 |
Why?
|
| Veterans | 1 | 1996 | 1755 | 0.000 |
Why?
|
| Palliative Care | 1 | 1987 | 427 | 0.000 |
Why?
|
| Immunotherapy | 1 | 1988 | 670 | 0.000 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 1987 | 931 | 0.000 |
Why?
|